Focus on Pancreatic Cancer
“In situations when the cancer has progressed following surgery, options like Abraxane can help prolong a patient’s life
The U.S. Food and Drug Administration has expanded the approved uses of Abraxane (paclitaxel protein-bound particles for injectable suspension, albumin-bound) to treat patients with late-stage (metastatic) pancreatic cancer.
A four-drug chemotherapy regimen has produced the longest improvement in survival ever seen in a phase III clinical trial of people with metastatic pancreatic cancer, one of the deadliest types of cancer.
Pancreatic cancer develops and spreads much more slowly than scientists have thought, according to new research from Johns Hopkins investigators. The finding indicates that there is a potentially broad window for diagnosis and prevention of the disease.